Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Justin Stebbing, MD, PhD from Imperial College Healthcare NHS Trust, UK, presents results from a double-blind phase III study comparing the efficacy and safety of CT-P6, a trastuzumab biosimilar candidate, versus traztuzumab as neoadjuvant treatment in HER2-postivie early breast cancer.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.